Why Are 10x Genomics (TXG) Shares Soaring Today

via StockStory
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

TXG Cover Image

What Happened?

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.1% in the morning session after Bank of America raised its price target on the stock to $80 from $50 while keeping a Neutral rating. 

The firm cited improving sentiment, growing consumables revenue, and initial traction for the Atera platform as positive drivers for the business. Bank of America maintained its Neutral rating on the stock despite the higher price target. The firm pointed to hardware revenue volatility and operating losses as ongoing factors offsetting the progress in consumables revenue and the Atera platform.

Is now the time to buy 10x Genomics? Access our full analysis report here, it’s free.

What Is The Market Telling Us

10x Genomics’s shares are extremely volatile and have had 60 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 11 days ago when the stock gained 2.8% on the news that Argus analyst John Eade initiated coverage on the company with a Buy rating. The new coverage established Argus's formal research tracking of 10x Genomics. An analyst initiation occurs when an investment research firm begins publishing regular analysis and investment recommendations on a security. 

A Buy rating indicates an expectation that the stock will deliver positive returns or outperform benchmark averages over an investment timeframe. New coverage initiations often draw increased attention from investors, contributing to positive trading momentum. 

10x Genomics is up 391% since the beginning of the year, but at $81.59 per share, it is still trading 16.5% below its 52-week high of $97.74 from October 2026. Despite the year-to-date gain, investors who bought $1,000 worth of 10x Genomics’s shares 5 years ago would now be looking at only $522.78.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article